Novo Nordisk A/S Stock Hits New 52-Week High (NVO)
Novo Nordisk A/S (NYSE:NVO) hit a new 52-week high Thursday as it is currently trading at $170.43, above its previous 52-week high of $170.27 with 210,750 shares traded as of 1:10 p.m. ET. Average volume has been 412,000 shares over the past 30 days.
Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model. NEW YORK ( TheStreet) -- Novo Nordisk A/S (NYSE: NVO) hit a new 52-week high Thursday as it is currently trading at $170.43, above its previous 52-week high of $170.27 with 210,750 shares traded as of 1:10 p.m. ET. Average volume has been 412,000 shares over the past 30 days. Novo Nordisk A/S has a market cap of $97.78 billion and is part of the health care sector and drugs industry. Shares are up 3.3% year to date as of the close of trading on Wednesday. Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products in Denmark and internationally. The company operates in two segments, Diabetes Care and Biopharmaceuticals. The company has a P/E ratio of four, below the S&P 500 P/E ratio of 17.7.
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
TheStreet Ratings rates Novo Nordisk A/S as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. You can view the full Novo Nordisk A/S Ratings Report. See all 52-week high stocks or get investment ideas from our investment research center. Holiday Special: Subscribe to Action Alerts PLUS to see how Jim Cramer trades his $2.5 Million+ portfolio for 51% off the list price. Your first 14-days are FREE: Sign up today to get e-mail alerts before every trade.